格隆汇11月12日｜长春高新(000661.SZ)公告称，公司子公司百克生物收到国家药品监督管理局对其吸 附无细胞百(二组分)白破联合疫苗(成人及青少年用)的《药物临床试验批准通知书》。该疫苗是一种可 以同时预防青少年及成人百日咳、白喉、破伤风的疫苗，接种对象为10周岁及以上人群。若该疫苗顺利 完成临床试验并获批上市，将进一步完善公司疫苗研发管线，丰富公司联合疫苗产品矩阵，有助于公司 优化产品结构和主营业务的全面发展。 ...

Core Viewpoint - The approval of the clinical trial for the adolescent and adult combined vaccine by the National Medical Products Administration represents a significant advancement for the company in expanding its vaccine development pipeline and product offerings [1] Group 1: Vaccine Approval - The company has received the clinical trial approval notice for the acellular combined vaccine (DTPa) for adolescents and adults [1] - This vaccine aims to simultaneously prevent whooping cough, diphtheria, and tetanus in individuals aged 10 years and older [1] Group 2: Market Impact - Successful completion of the clinical trials and subsequent market approval will enhance the company's vaccine research and development pipeline [1] - The new vaccine will diversify the company's combined vaccine product matrix, optimizing its product structure and supporting comprehensive business development [1] - This development is expected to provide higher quality vaccination options for the public and create new growth points for the company's performance [1]

Core Viewpoint - The company, 百克生物 (Biokangtai), has received approval from the National Medical Products Administration for its acellular combined vaccine for adolescents and adults, which targets whooping cough, diphtheria, and tetanus [1] Group 1: Product Approval - The company has been granted a clinical trial approval notice for the acellular combined whooping cough, diphtheria, and tetanus vaccine for adolescents and adults [1] - This vaccine is designed to simultaneously prevent whooping cough, diphtheria, and tetanus in individuals aged 10 years and older [1] - The vaccine aims to stimulate an immune response to prevent invasive infections caused by these diseases [1]